Cargando…

Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration

BACKGROUND: In 2000, American Samoa had 16.5% prevalence of lymphatic filariasis (LF) antigenemia. Annual mass drug administration (MDA) was conducted using single-dose albendazole plus diethylcarbamazine from 2000 to 2006. This study presents the results of a 2007 population-based PacELF C-survey i...

Descripción completa

Detalles Bibliográficos
Autores principales: Coutts, Shaun P., King, Jonathan D., Pa’au, Molisamoa, Fuimaono, Saipale, Roth, Joseph, King, Mary Rose, Lammie, Patrick J., Lau, Colleen L., Graves, Patricia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543440/
https://www.ncbi.nlm.nih.gov/pubmed/28794687
http://dx.doi.org/10.1186/s41182-017-0063-8
_version_ 1783255149716701184
author Coutts, Shaun P.
King, Jonathan D.
Pa’au, Molisamoa
Fuimaono, Saipale
Roth, Joseph
King, Mary Rose
Lammie, Patrick J.
Lau, Colleen L.
Graves, Patricia M.
author_facet Coutts, Shaun P.
King, Jonathan D.
Pa’au, Molisamoa
Fuimaono, Saipale
Roth, Joseph
King, Mary Rose
Lammie, Patrick J.
Lau, Colleen L.
Graves, Patricia M.
author_sort Coutts, Shaun P.
collection PubMed
description BACKGROUND: In 2000, American Samoa had 16.5% prevalence of lymphatic filariasis (LF) antigenemia. Annual mass drug administration (MDA) was conducted using single-dose albendazole plus diethylcarbamazine from 2000 to 2006. This study presents the results of a 2007 population-based PacELF C-survey in all ages and compares the adult filarial antigenemia results of this survey to those of a subsequent 2010 survey in adults with the aim of improving understanding of LF transmission after MDA. RESULTS: The 2007 C-survey used simple random sampling of households from a geolocated list. In 2007, the overall LF antigen prevalence by immunochromatographic card test (ICT) for all ages was 2.29% (95% CI 1.66–3.07). Microfilaremia prevalence was 0.27% (95% CI 0.09–0.62). Increasing age (OR 1.04 per year, 95% CI 1.02–1.05) was significantly associated with ICT positivity on multivariate analysis, while having ever taking MDA was protective (OR 0.39, 95% CI 0.16–0.96). The 2010 survey used a similar spatial sampling design. The overall adult filarial antigenemia prevalence remained relatively stable between the surveys at 3.32% (95% CI 2.44–4.51) by ICT in 2007 and 3.23 (95% CI 2.21–4.69) by Og4C3 antigen in 2010. However, there were changes in village-level prevalence. Eight village/village groupings had antigen-positive individuals identified in 2007 but not in 2010, while three villages/village groupings that had no antigen-positive individuals identified in 2007 had positive individuals identified in 2010. CONCLUSIONS: After 7 years of MDA, with four rounds achieving effective coverage, a representative household survey in 2007 showed a decline in prevalence from 16.5 to 2.3% in all ages. However, lack of further decline in adult prevalence by 2010 and fluctuation at the village level showed that overall antigenemia prevalence at a broader scale may not provide an accurate reflection of ongoing transmission at the village level.
format Online
Article
Text
id pubmed-5543440
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55434402017-08-09 Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration Coutts, Shaun P. King, Jonathan D. Pa’au, Molisamoa Fuimaono, Saipale Roth, Joseph King, Mary Rose Lammie, Patrick J. Lau, Colleen L. Graves, Patricia M. Trop Med Health Research BACKGROUND: In 2000, American Samoa had 16.5% prevalence of lymphatic filariasis (LF) antigenemia. Annual mass drug administration (MDA) was conducted using single-dose albendazole plus diethylcarbamazine from 2000 to 2006. This study presents the results of a 2007 population-based PacELF C-survey in all ages and compares the adult filarial antigenemia results of this survey to those of a subsequent 2010 survey in adults with the aim of improving understanding of LF transmission after MDA. RESULTS: The 2007 C-survey used simple random sampling of households from a geolocated list. In 2007, the overall LF antigen prevalence by immunochromatographic card test (ICT) for all ages was 2.29% (95% CI 1.66–3.07). Microfilaremia prevalence was 0.27% (95% CI 0.09–0.62). Increasing age (OR 1.04 per year, 95% CI 1.02–1.05) was significantly associated with ICT positivity on multivariate analysis, while having ever taking MDA was protective (OR 0.39, 95% CI 0.16–0.96). The 2010 survey used a similar spatial sampling design. The overall adult filarial antigenemia prevalence remained relatively stable between the surveys at 3.32% (95% CI 2.44–4.51) by ICT in 2007 and 3.23 (95% CI 2.21–4.69) by Og4C3 antigen in 2010. However, there were changes in village-level prevalence. Eight village/village groupings had antigen-positive individuals identified in 2007 but not in 2010, while three villages/village groupings that had no antigen-positive individuals identified in 2007 had positive individuals identified in 2010. CONCLUSIONS: After 7 years of MDA, with four rounds achieving effective coverage, a representative household survey in 2007 showed a decline in prevalence from 16.5 to 2.3% in all ages. However, lack of further decline in adult prevalence by 2010 and fluctuation at the village level showed that overall antigenemia prevalence at a broader scale may not provide an accurate reflection of ongoing transmission at the village level. BioMed Central 2017-08-04 /pmc/articles/PMC5543440/ /pubmed/28794687 http://dx.doi.org/10.1186/s41182-017-0063-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Coutts, Shaun P.
King, Jonathan D.
Pa’au, Molisamoa
Fuimaono, Saipale
Roth, Joseph
King, Mary Rose
Lammie, Patrick J.
Lau, Colleen L.
Graves, Patricia M.
Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title_full Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title_fullStr Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title_full_unstemmed Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title_short Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
title_sort prevalence and risk factors associated with lymphatic filariasis in american samoa after mass drug administration
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543440/
https://www.ncbi.nlm.nih.gov/pubmed/28794687
http://dx.doi.org/10.1186/s41182-017-0063-8
work_keys_str_mv AT couttsshaunp prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT kingjonathand prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT paaumolisamoa prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT fuimaonosaipale prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT rothjoseph prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT kingmaryrose prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT lammiepatrickj prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT laucolleenl prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration
AT gravespatriciam prevalenceandriskfactorsassociatedwithlymphaticfilariasisinamericansamoaaftermassdrugadministration